<DOC>
	<DOCNO>NCT01772732</DOCNO>
	<brief_summary>The primary objective ass safety tolerability multiple dos Simotinib Hydrochloride NSCLC patient . The secondary objective determine pharmacokinetic ( PK ) profile explore preliminary anti-tumor activity .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Multiple Ascending Doses Simotinib Hydrochloride Patients With Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients histologically cytologically confirm diagnosis advance NSCLC , previously treat least one platinumbased chemotherapy regimen , disease relapse ; Patients end chemotherapy radiotherapy least 4 week prior study entry recover previous toxicity ; EGFR mutation positive ( E19del、L858R、L861Q、G719X , etc . ) ; Patients least one measurable lesion meeting RECIST ; ECOG performance status 02 ; Life expectancy ≥12 week ; Adequate bone marrow function : ANC ≥1.5 × 109/L , PLT≥80 ×109/L , HB ≥90 g/L ; Adequate hepatic function : serum bilirubin ≤ 2 × ULN , AST ALT ≤ 2.5 × ULN , ≤ 5 × ULN acceptable liver tumor involvement ; Adequate renal function : endogenous creatinine clearance rate ( CrCl ) ≥ 60 mL/min serum creatinine ≤ 1.5 × ULN ; Females childbearing potential must negative pregnancy test within 7 day prior treatment use approve contraceptive method study ; Males must surgically sterile use approve contraceptive method study . Patients previously treat EGFR inhibitor molecular target drug ( micromolecular drug monoclonal antibody ) Iressa , Tarceva , Sutent , Nexavar , Sprycel , Erbitux , Nimotuzumab , Icotinib , Herceptin , etc . ; The know hypersensitivity Simotinib excipients ; Concurrent treatment rifampin , rifabutin , rifapentine , dexamethasone , phenytoin sodium , carbamazepine , phenobarbital , Hypericum perforatum , atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin ; CNS metastasis diagnose recently receive surgery radiotherapy ; Evidence interstitial lung disease ; Preexisting idiopathic pulmonary fibrosis evidence CT scan baseline ; Any serious uncontrollable systemic disease ( unstable respiratory disorder , cardiovascular , hepatic kidney disorder ) ; Any unstable systemic disorder ( include active infection , uncontrollable hypertension , unstable angina pectoris , congestive heart failure , liver kidney disorder metabolism disease ) ; Other malignancy diagnose within last 5 year exception completely cure cervical cancer situ , basal squamous cell skin cancer ; Any remarkable eye disorder , especially severe dry eye syndrome , keratoconjunctivitis sicca , herpes keratitis ; History nerve psychiatric disorder , include epilepsy dementia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Simotinib</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
</DOC>